Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Michael Anderson, PhD and Susan Leigh Anderson, PhD
Two concerns (unknowability of how output is derived from input and overreliance on clinical decision support systems) are main sources of ethical questions about AI in health care.
AMA J Ethics. 2019;21(2):E125-130. doi:
10.1001/amajethics.2019.125.
This article considers that benefits of using humor in clinical settings come with risks of diminishing therapeutic capacity in patient-clinician relationships.
AMA J Ethics. 2020;22(7):E576-582. doi:
10.1001/amajethics.2020.576.
Joshua Nagler, MD, MHPEd and Rebekah Mannix, MD, MPH
Humor can help motivate positive interactions amidst fast-paced clinical encounters but can alienate colleagues when weaponized to promote assumed superiority of an individual or group.
AMA J Ethics. 2020;22(7):E583-587. doi:
10.1001/amajethics.2020.583.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022;24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.